CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity

References

• Grignon DJ, Che M. Clear cell renal cell carcinoma. Clin Lab Med. 2005;25(2):305–316. doi:10.1016/j.cll.2005.01.012
   PubMed Web of Science ®Google Scholar
• Perazella MA, Dreicer R, Rosner MH. Renal cell carcinoma for the nephrologist. Kidney Int. 2018;94(3):471–483. doi:10.1016/j.kint.2018.01.023
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.21411
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–720. doi:10.1093/annonc/mdz056
   PubMed Web of Science ®Google Scholar
• Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011;11(10):708–718. doi:10.1038/nrc3124
   PubMed Web of Science ®Google Scholar
• Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci U S A. 2008;105(32):11043–11049. doi:10.1073/pnas.0802862105
   PubMed Web of Science ®Google Scholar
• Kwon NH, Fox PL, Kim S. Aminoacyl-tRNA synthetases as therapeutic targets. Nat Rev Drug Discov. 2019;18(8):629–650. doi:10.1038/s41573-019-0026-3
   PubMed Web of Science ®Google Scholar
• Tian T, Xiao L, Du J, et al. Polymorphisms in CARS are associated with gastric cancer risk: a Two-Stage Case-Control Study in the Chinese population. Gastric Cancer. 2017;20(6):940–947. doi:10.1007/s10120-017-0717-6
   PubMed Web of Science ®Google Scholar
• Cho S, Kim SB, Lee Y. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1. J Immunother Cancer. 2020;8(1):e000277. doi:10.1136/jitc-2019-000277
   PubMed Web of Science ®Google Scholar
• Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell. 2018;173(2):283–285. doi:10.1016/j.cell.2018.03.042
   PubMed Web of Science ®Google Scholar
• Zhang J, Bajari R, Andric D. The international cancer genome consortium data portal. Nat Biotechnol. 2019;37(4):367–369. doi:10.1038/s41587-019-0055-9
   PubMed Web of Science ®Google Scholar
• Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11(16):5730–5739. doi:10.1158/1078-0432.CCR-04-2225
   PubMed Web of Science ®Google Scholar
• A-llopis PE, Vega-Rub N-de-Celis S, Liao A. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751–759. doi:10.1038/ng.2323
   PubMed Web of Science ®Google Scholar
• A-llopis PE, Brugarolas J. Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. Nat Protoc. 2013;8(11):2240–2255. doi:10.1038/nprot.2013.141
   PubMed Web of Science ®Google Scholar
• Von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810. doi:10.1158/0008-5472.CAN-14-0210
   PubMed Web of Science ®Google Scholar
• Wotschofsky Z, Gummlich L, Liep J, et al. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. PLoS One. 2016;11(2):e0148746. doi:10.1371/journal.pone.0148746
   PubMed Web of Science ®Google Scholar
• Liep J, Kilic E, Meyer HA, et al. Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One. 2016;11(6):e0157801. doi:10.1371/journal.pone.0157801
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
   PubMed Web of Science ®Google Scholar
• Timmermann B, Kerick M, Roehr C, et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010;5(12):e15661. doi:10.1371/journal.pone.0015661
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153–162. doi:10.1038/nrclinonc.2009.237
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183. doi:10.1186/s40425-019-0647-4
   PubMed Web of Science ®Google Scholar
• Jia J, Li B, Jin Y, et al. Expression, purification, and characterization of human tyrosyl-tRNA synthetase. Protein Expr Purif. 2003;27(1):104–108. doi:10.1016/S1046-5928(02)00576-4
   PubMed Web of Science ®Google Scholar
• Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med. 2019;17(1):309.
   PubMed Web of Science ®Google Scholar
• Garcia MA, Nelson WJ, Chavez N. Cell-cell junctions organize structural and signaling networks. Cold Spring Harb Perspect Biol. 2018;10(4):a029181. doi:10.1101/cshperspect.a029181
   PubMed Web of Science ®Google Scholar
• Hämälistö S, Stahl JL, Favaro E. Spatially and temporally defined lysosomal leakage facilitates mitotic chromosome segregation. Nat Commun. 2020;11(1):229. doi:10.1038/s41467-019-14009-0
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Par L, Pascual T, Segu E, et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018;29(10):2121–2128. doi:10.1093/annonc/mdy335
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N. CTLA-4: a moving target in immunotherapy. Blood J Am Soc Hematol. 2018;131(1):58–67.
   Google Scholar
• Lichtenegger FS, Rothe M, Schnorfeil FM, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;9(385).
   PubMedGoogle Scholar
• Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017;66(8):1463–1473. doi:10.1136/gutjnl-2016-311421
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-2428
   PubMed Web of Science ®Google Scholar
• Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276(1):66–79. doi:10.1111/imr.12525
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001
   PubMed Web of Science ®Google Scholar